Full Breakdown
Silicon Valley Billionaires Back First Human Cellular Reprogramming Trial for Glaucoma
By Drooid · · How we work
Core Event: Phase 1 Safety Trial of ER-100 Shows Tolerability in Glaucoma Patients
Life Biosciences initiated a first-in-human, open-label Phase 1 study (NCT07290244) of its epigenetic-restoration therapy ER-100 in adults with open-angle glaucoma. Three participants received a single intravitreal injection of Dose Level 1 (2 × 10¹¹ vg) together with eight weeks of oral doxycycline to induce expression of the OSK transcription factors (OCT4, SOX2, KLF4). Administration was well-tolerated through Day 56, and two participants demonstrated measurable improvements on standard visual-field testing. The Data Safety Monitoring Board subsequently approved escalation to Dose Level 2.
Background & Context: Longevity Science Attracts Billionaire Funding
Cellular reprogramming—temporarily resetting mature cells to a more youthful state—has reversed age-related decline in mice and monkeys. Silicon Valley investors Jeff Bezos, Peter Thiel, Yuri Milner and Sam Altman have poured capital into startups pursuing this “master key” approach. Altos Labs, backed by Bezos, hired clinical-trial veteran Joan Mannick; Thiel’s Founders Fund backed New Limit, which aims for a liver-cell reprogramming trial in 2027; and Altman-backed Retro Biosciences is also exploring the technology. Life Biosciences is the first company to test cellular reprogramming in humans, targeting optic neuropathies such as glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).
Data & Statistics
- Participants: 3 adults with open-angle glaucoma
- Dose: 2 × 10¹¹ vg ER-100 (intravitreal) plus daily doxycycline for 56 days
- Safety: No major adverse events reported through Day 56 (October 8, 2026)
- Efficacy signal: Visual-field improvement observed in 2 of 3 participants
Conflicting Reports & Gaps
The trial’s small size and short follow-up period leave uncertainty about long-term safety, durability of visual improvement, and applicability to other optic neuropathies. No comparative data exist yet to determine whether the observed visual-field gains exceed expected variability in standard glaucoma monitoring.
What’s Next
Following the safety board’s endorsement, the study will enroll a second cohort at a higher dose level. Life Biosciences plans to expand the program to include patients with non-arteritic anterior ischemic optic neuropathy and to explore applications of cellular reprogramming for other age-related organ systems.
Verbatim Quotes
- “We believe it has the potential to really be a master key to address a broad range of age-related diseases," Ringel said.” — Michael Ringel